C4 Therapeutics
$4.10
95
-$0.14-3.3% Thursday 20:00
+$0.04+0.98%Thursday 23:50After hours
Statistics
Day High
4.1
Day Low
4.09
52W High
5.17
52W Low
1.69
Volume
47,169
Avg. Volume
-
Mkt Cap
504.4M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.49
-0.39
-0.28
-0.18
Expected EPS
-0.2194
Actual EPS
N/A
Financials
-292.08%Profit Margin
Unprofitable35.95MRevenue
-104.99MNet Income
Analyst Ratings
12.00Average Price Target
The highest estimate is 12.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow CCCC. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap301.95B
Roche
RHHBY
Mkt Cap334.28B
AMGEN
AMGN
Mkt Cap237.52B
Bristol-Myers Squibb
BMY
Mkt Cap136.88B
Gilead Sciences
GILD
Mkt Cap181.18B
Merck
MRK
Mkt Cap376.37B
Pfizer
PFE
Mkt Cap159.99B
Abbvie
ABBV
Mkt Cap468.22B
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
About
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Show more...
CEO
Andrew J. Hirsch
Employees
104
Country
United States
ISIN
US12529R1077
Listings
1 Comments
FAQ
What is C4 Therapeutics stock price today?▼
The current price of CCCC is $4.10 USD — it has decreased by -3.3% in the past 24 hours. Watch C4 Therapeutics stock price performance more closely on the chart.
What is C4 Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange C4 Therapeutics stocks are traded under the ticker CCCC.
Is C4 Therapeutics stock price growing?▼
CCCC stock has risen by +2.5% compared to the previous week, the month change is a +15.49% rise, over the last year C4 Therapeutics has showed a +60.78% increase.
What is C4 Therapeutics market cap?▼
Today C4 Therapeutics has the market capitalization of 504.4M
When is the next C4 Therapeutics earnings date?▼
C4 Therapeutics is going to release the next earnings report on October 29, 2026.
What were C4 Therapeutics earnings last quarter?▼
CCCC earnings for the last quarter are -0.18 USD per share, whereas the estimation was -0.23 USD resulting in a +20.49% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is C4 Therapeutics revenue for the last year?▼
C4 Therapeutics revenue for the last year amounts to 35.95M USD.
What is C4 Therapeutics net income for the last year?▼
CCCC net income for the last year is -104.99M USD.
How many employees does C4 Therapeutics have?▼
As of August 28, 2026, the company has 104 employees.
In which sector is C4 Therapeutics located?▼
C4 Therapeutics operates in the Health & Wellness sector.
When did C4 Therapeutics complete a stock split?▼
C4 Therapeutics has not had any recent stock splits.
Where is C4 Therapeutics headquartered?▼
C4 Therapeutics is headquartered in WATERTOWN, United States.